Jennifer G Robinson1, Benjamin Booth. 1. Department of Epidemiology & Medicine, University of Iowa, Iowa City, IA 52242, USA. jennifer-g-robinson@uiowa.edu
Abstract
BACKGROUND: Statins are the evidence-based drugs of choice for the prevention of cardiovascular disease (CVD). OBJECTIVE: Statin use has increased in those ≥ 65 years, but patterns of use in subgroups of elderly are unknown. METHODS: Weighted data from the 2001 through 2006 National Health and Nutrition Examination Surveys were combined for this analysis. RESULTS: Statin use increased in all sex, age, and risk categories between the 2001-2002 and 2005-2006 surveys, when the greatest use was by men 65 to 74 years of age with CVD (80%), followed by women with CVD who were 65-79 of age (64%-69%), women and men with diabetes who were 65-69 years of age (56% and 94%, respectively); statins were used by <42% of patients without CVD or diabetes. In adjusted logistic regression models, those with diabetes (odds ratio [OR] 2.1, 95% confidence intervals [95% CI] 1.8-2.6), CVD but no diabetes (OR 3.0, 95% CI 2.5-3.6), and CVD and diabetes (OR 5.2, 95% CI 3.9-7.1) were more likely to use statins than those without CVD or diabetes (P ≤ .001). A significant interaction between age and sex was found, where 75- to 79-year-old women were more likely to report statin use than men 65-69 years of age (OR 2.07, 95% CI 1.29-3.35). In general, those ages 65-69 years were more likely to use a statin than those ≥ 70 years (OR 0.57, 95% CI 0.39-1.08, P = .08). Nonwhite persons aged ≥ 70 years reported less statin use than whites aged 65-69 (OR 0.17, 95% CI 0.10-0.30). Mexican-American subjects were less likely to report statin use than whites. CONCLUSIONS: Although statin use has increased substantially over time, statins remain underused in both the primary and secondary prevention of CVD in the elderly, with some evidence of disparities by sex, advancing age, and race/ethnicity.
BACKGROUND: Statins are the evidence-based drugs of choice for the prevention of cardiovascular disease (CVD). OBJECTIVE: Statin use has increased in those ≥ 65 years, but patterns of use in subgroups of elderly are unknown. METHODS: Weighted data from the 2001 through 2006 National Health and Nutrition Examination Surveys were combined for this analysis. RESULTS: Statin use increased in all sex, age, and risk categories between the 2001-2002 and 2005-2006 surveys, when the greatest use was by men 65 to 74 years of age with CVD (80%), followed by women with CVD who were 65-79 of age (64%-69%), women and men with diabetes who were 65-69 years of age (56% and 94%, respectively); statins were used by <42% of patients without CVD or diabetes. In adjusted logistic regression models, those with diabetes (odds ratio [OR] 2.1, 95% confidence intervals [95% CI] 1.8-2.6), CVD but no diabetes (OR 3.0, 95% CI 2.5-3.6), and CVD and diabetes (OR 5.2, 95% CI 3.9-7.1) were more likely to use statins than those without CVD or diabetes (P ≤ .001). A significant interaction between age and sex was found, where 75- to 79-year-old women were more likely to report statin use than men 65-69 years of age (OR 2.07, 95% CI 1.29-3.35). In general, those ages 65-69 years were more likely to use a statin than those ≥ 70 years (OR 0.57, 95% CI 0.39-1.08, P = .08). Nonwhite persons aged ≥ 70 years reported less statin use than whites aged 65-69 (OR 0.17, 95% CI 0.10-0.30). Mexican-American subjects were less likely to report statin use than whites. CONCLUSIONS: Although statin use has increased substantially over time, statins remain underused in both the primary and secondary prevention of CVD in the elderly, with some evidence of disparities by sex, advancing age, and race/ethnicity.
Authors: C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes Journal: Lancet Date: 2005-09-27 Impact factor: 79.321
Authors: Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn Journal: N Engl J Med Date: 2008-11-09 Impact factor: 91.245
Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone Journal: Circulation Date: 2004-07-13 Impact factor: 29.690
Authors: Earl S Ford; Umed A Ajani; Janet B Croft; Julia A Critchley; Darwin R Labarthe; Thomas E Kottke; Wayne H Giles; Simon Capewell Journal: N Engl J Med Date: 2007-06-07 Impact factor: 91.245
Authors: Zachary A Marcum; Yan Zheng; Subashan Perera; Elsa Strotmeyer; Anne B Newman; Eleanor M Simonsick; Ronald I Shorr; Douglas C Bauer; Julie M Donohue; Joseph T Hanlon Journal: Res Social Adm Pharm Date: 2013-01-04
Authors: Joseph T Hanlon; Robert M Boudreau; Subashan Perera; Elsa S Strotmeyer; Anne B Newman; Eleanor M Simonsick; Ronald I Shorr; Douglas C Bauer; Julie M Donohue Journal: Am Heart J Date: 2013-08-28 Impact factor: 4.749